why are you telling me the obvious? my point is that I do not need him to buy me LPL at huge premium, he should look for oil and find them like others do at a cost of $2/ BRL. If oil takes a dive, this pathetic company will have problem servicing debt, and will go belly up.
These guys are going around and buying other companies at premium, and then delivering nothing. One to have to ask Schiller, what have you done with what you already have? you have lost shareholders money. I could have bought EPL at the market yesterday for $9 less than you paid for it today, where is your value creation. Your stock has been one of the worst performing over the last few years, please leave.
Does anyone know what is going on, I like the earning up this morning, but I am new and want to know what is going on specially with inventories.
This is not a management team, these are bunch of fradulant thieves, never heard it being so bad, bunch of voltures helping themeselves to the shareholder equities, very abussive. Good that thry sre being sued, law suit should be supported.
There is 3 events that can happen when safety committee reviews the results. The committee reviews the results to make sure that patients on the drug are not being harmed, that is the reason for this review. Bad thing to happen would be that they stop the trial if patients are being harmed, the good thing would be they say it is OK to go on and no one is being harmed, the best thing that happens very rarely is they say this is a murder if we don't give this to everyone and they sunblind the trial and give the drug to everyone, they don't do that on every time a drug works. Stopping the trial because drug works is a risky proposition, and that is why it is extremely rare, you basically forego all plans, and wreck the trial, so they need to be dead certain when they do that. In conclusion, at the least this stock should not go down today, it should actually move up a bit.
Not true at all, it is great if they stop the study, but that is once in a moon event. Almost all cancer drugs have run their course of planned study before getting approved.
I guess market as expecting the drug would work so well that they would have stopped the trial and give the drug to everyone, that is very unusual event, and expectation should not have been that high, even though it would have been nice to have that.
She has had miserable track record of selling, she has been selling stock when it was at teens, so don't look at her as a guidance, she is a dummy.
They were prevented from putting 35 wells on production due to weather. I think analysts will be very positive, and stock will rally after perhaps an initial drop on headline news.
The lower end of next years EPS guidance is $8, a PE of 30 which would be very reasonable, will result on a $240 price next year. listening to conference call, any concern with CFO resignation is misplaced. With the price of stock appreciating the way it has, many management members get rich and want to live it up.
He has been attacking small cap Biotech, and since 90% of drug small caps develop fails ( according to Adam himself ), he mostly by chance has developed a fearsome reputation, but every hot hand eventually comes to an end, and this stock will bring down Adam's empire.
Expecting cure for this type of disease is like expecting Reagan would have taken a pill and next thing you know from wearing diapers back to running for office again and giving speeches. AF's assertion that this was not a cure is stupid. Any drug developed in this area will be a prevention and slowing of progression. That will be a huge market as so many people, 1/3 of population develop dementia. So give me a pill that prevent me going the road that my mother did, and I will take it any day.
When you combine the " improvement in function " with MRI results, you have to conclude that It most likely will be progression free and may be some reversal as well. My mother has Az, and no way any drus would restore a brain that has already been dead.
Improvement in executive function is huge. That means anyone with early stage disease can take this and not proceed to develop the full disease. Once the disease is fully ravaged the brain, it would be unrealistic to expect a drug to bring back the dead, but stopping the disease at it's track which this test implies is humongous market potential. AF and Street are short this stock, and now defending their turf.
The way I look at it a major pharma paid them $50 million upfront and promiss of another $500 to come and then royalties on sale, that not even including the north America. you take out $5/ share cash, and you buying such a promising drug, and othes in the pipeline for $8/share. I am buying baby, yes I am.